{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:00:42Z","timestamp":1793336442752,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T00:00:00Z","timestamp":1561507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s10637-019-00813-4","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T02:04:03Z","timestamp":1561514643000},"page":"634-649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tetra-substituted pyrrole derivatives act as potent activators of p53 in melanoma cells"],"prefix":"10.1007","volume":"38","author":[{"given":"Maria Chiara","family":"Proto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Forte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cuozzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ramunno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Fattorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Gazzerro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pascale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7412-7918","authenticated-orcid":false,"given":"Silvia","family":"Franceschelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,26]]},"reference":[{"issue":"7","key":"813_CR1","doi-asserted-by":"publisher","first-page":"2301s","DOI":"10.1158\/1078-0432.CCR-14-1215","volume":"12","author":"FG Haluska","year":"2006","unstructured":"Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V (2006) Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 12(7 Pt 2):2301s\u20132307s. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1215","journal-title":"Clin Cancer Res"},{"key":"813_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-85","volume":"10","author":"PA Ascierto","year":"2012","unstructured":"Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N (2012) The role of BRAF V600 mutation in melanoma. J Transl Med 10:85. https:\/\/doi.org\/10.1186\/1479-5876-10-85","journal-title":"J Transl Med"},{"key":"813_CR3","doi-asserted-by":"publisher","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur G, BRIM-3 Study Group. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507\u20132516. https:\/\/doi.org\/10.1056\/NEJMoa1103782","DOI":"10.1056\/NEJMoa1103782"},{"issue":"9839","key":"813_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358\u2013365. https:\/\/doi.org\/10.1016\/S0140-6736(12)60868-X","journal-title":"Lancet"},{"issue":"3","key":"813_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.bcp.2011.05.015","volume":"82","author":"IV Fedorenko","year":"2011","unstructured":"Fedorenko IV, Paraiso KH, Smalley KS (2011) Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol 82(3):201\u2013209. https:\/\/doi.org\/10.1016\/j.bcp.2011.05.015","journal-title":"Biochem Pharmacol"},{"issue":"166","key":"813_CR6","doi-asserted-by":"publisher","first-page":"pe16","DOI":"10.1126\/scisignal.2001948","volume":"4","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos PI, Solit DB (2011) Resistance to MEK inhibitors: should we co-target upstream? Sci Signal 4(166):pe16. https:\/\/doi.org\/10.1126\/scisignal.2001948","journal-title":"Sci Signal"},{"issue":"2","key":"813_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, DiCara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DSB, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L (2012) A landscape of driver mutations in melanoma. Cell 150(2):251\u2013263. https:\/\/doi.org\/10.1016\/j.cell.2012.06.024","journal-title":"Cell"},{"issue":"8","key":"813_CR8","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/nm.2863","volume":"18","author":"A Gembarska","year":"2012","unstructured":"Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip D, Goydos J, Haigh JJ, Haupt Y, Larue L, Jochemsen A, Shi H, Moriceau G, Lo RS, Ghanem G, Shackleton M, Bernal F, Marine JC (2012) MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med 18(8):1239\u20131247. https:\/\/doi.org\/10.1038\/nm.2863","journal-title":"Nat Med"},{"issue":"9","key":"813_CR9","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nrm2451","volume":"9","author":"F Murray-Zmijewski","year":"2008","unstructured":"Murray-Zmijewski F, Slee EA, Lu X (2008) A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol 9(9):702\u2013712. https:\/\/doi.org\/10.1038\/nrm2451","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"28","key":"813_CR10","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1038\/onc.2016.502","volume":"36","author":"M Fischer","year":"2017","unstructured":"Fischer M (2017) Census and evaluation of p53 target genes. Oncogene 36(28):3943\u20133956. https:\/\/doi.org\/10.1038\/onc.2016.502","journal-title":"Oncogene"},{"issue":"5659","key":"813_CR11","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303(5659):844\u2013848. https:\/\/doi.org\/10.1126\/science.1092472","journal-title":"Science"},{"issue":"2","key":"813_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/jid.2011.313","volume":"132","author":"Z Ji","year":"2012","unstructured":"Ji Z, Njauw CN, Taylor M, Neel V, Flaherty KT, Tsao H (2012) p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J Invest Dermatol 132(2):356\u2013364. https:\/\/doi.org\/10.1038\/jid.2011.313","journal-title":"J Invest Dermatol"},{"issue":"5","key":"813_CR13","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ccr.2013.03.013","volume":"23","author":"M Lu","year":"2013","unstructured":"Lu M, Breyssens H, Salter V, Zhong S, Hu Y, Baer C, Ratnayaka I, Sullivan A, Brown NR, Endicott J, Knapp S, Kessler BM, Middleton MR, Siebold C, Jones EY, Sviderskaya EV, Cebon J, John T, Caballero OL, Goding CR, Lu X (2013) Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1\/CDK1-phosphorylated nuclear iASPP. Cancer Cell 23(5):618\u2013633. https:\/\/doi.org\/10.1016\/j.ccr.2013.03.013","journal-title":"Cancer Cell"},{"issue":"17","key":"813_CR14","doi-asserted-by":"publisher","first-page":"6666","DOI":"10.1021\/jm400947b","volume":"56","author":"M Persico","year":"2013","unstructured":"Persico M, Ramunno A, Maglio V, Franceschelli S, Esposito C, Carotenuto A, Brancaccio D, De Pasquale V, Pavone LM, Varra M, Orteca N, Novellino E, Fattorusso C (2013) New anticancer agents mimicking protein recognition motifs. J Med Chem 56(17):6666\u20136680. https:\/\/doi.org\/10.1021\/jm400947b","journal-title":"J Med Chem"},{"key":"813_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.biocel.2014.11.015","volume":"59","author":"CK Hind","year":"2015","unstructured":"Hind CK, Carter MJ, Harris CL, Chan HT, James S, Cragg MS (2015) Role of the pro-survival molecule Bfl-1 in melanoma. Int J Biochem Cell Biol 59:94\u2013102. https:\/\/doi.org\/10.1016\/j.biocel.2014.11.015","journal-title":"Int J Biochem Cell Biol"},{"key":"813_CR16","doi-asserted-by":"publisher","unstructured":"Esposito T, Sansone F, Franceschelli S, Del Gaudio P, Picerno P, Aquino RP, Mencherini T (2017) Hazelnut (Corylus avellana L.) shells extract: phenolic composition, antioxidant effect and cytotoxic activity on human Cancer cell lines. Int J Mol Sci 18(2). pii: E392. https:\/\/doi.org\/10.3390\/ijms18020392","DOI":"10.3390\/ijms18020392"},{"issue":"3","key":"813_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1021\/acs.jafc.5b05404","volume":"64","author":"AL Piccinelli","year":"2016","unstructured":"Piccinelli AL, Pagano I, Esposito T, Mencherini T, Porta A, Petrone AM, Gazzerro P, Picerno P, Sansone F, Rastrelli L, Aquino RP (2016) HRMS profile of a hazelnut skin Proanthocyanidin-rich fraction with antioxidant and anti-Candida albicans activities. J Agric Food Chem 64(3):585\u2013595. https:\/\/doi.org\/10.1021\/acs.jafc.5b05404","journal-title":"J Agric Food Chem"},{"issue":"1","key":"813_CR18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jcp.22727","volume":"227","author":"MC Proto","year":"2012","unstructured":"Proto MC, Gazzerro P, Di Croce L, Santoro A, Malfitano AM, Pisanti S, Laezza C, Bifulco M (2012) Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth. J Cell Physiol 227(1):250\u2013258. https:\/\/doi.org\/10.1002\/jcp.22727","journal-title":"J Cell Physiol"},{"key":"813_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul 22:27\u201355","journal-title":"Adv Enzym Regul"},{"issue":"1","key":"813_CR20","first-page":"171","volume":"23","author":"P Gazzerro","year":"2010","unstructured":"Gazzerro P, Malfitano AM, Proto MC, Santoro A, Pisanti S, Caruso MG, Notarnicola M, Messa C, Laezza C, Misso G, Caraglia M, Bifulco M (2010) Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin. Oncol Rep 23(1):171\u2013175","journal-title":"Oncol Rep"},{"key":"813_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00949","volume":"8","author":"D Fiore","year":"2018","unstructured":"Fiore D, Ramesh P, Proto MC, Piscopo C, Franceschelli S, Anzelmo S, Medema JP, Bifulco M, Gazzerro P (2018) Rimonabant kills Colon Cancer stem cells without inducing toxicity in Normal Colon organoids. Front Pharmacol 8:949. https:\/\/doi.org\/10.3389\/fphar.2017.00949","journal-title":"Front Pharmacol"},{"issue":"1","key":"813_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11688-x","volume":"7","author":"MC Proto","year":"2017","unstructured":"Proto MC, Fiore D, Piscopo C, Franceschelli S, Bizzarro V, Laezza C, Lauro G, Feoli A, Tosco A, Bifulco G, Sbardella G, Bifulco M, Gazzerro P (2017) Inhibition of Wnt\/\u03b2-catenin pathway and histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer. Sci Rep 7(1):11678. https:\/\/doi.org\/10.1038\/s41598-017-11688-x","journal-title":"Sci Rep"},{"key":"813_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jprot.2013.01.030","volume":"82","author":"F Dal Piaz","year":"2013","unstructured":"Dal Piaz F, Cotugno R, Lepore L, Vassallo A, Malafronte N, Lauro G, Bifulco G, Belisario MA, De Tommasi N (2013) Chemical proteomics reveals HSP70 1A as a target for the anticancer diterpene oridonin in Jurkat cells. J Proteome 82:14\u201326. https:\/\/doi.org\/10.1016\/j.jprot.2013.01.030","journal-title":"J Proteome"},{"issue":"10","key":"813_CR24","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1021\/acs.jnatprod.6b00627","volume":"79","author":"F Dal Piaz","year":"2016","unstructured":"Dal Piaz F, Vera Saltos MB, Franceschelli S, Forte G, Marzocco S, Tuccinardi T, Poli G, Nejad Ebrahimi S, Hamburger M, De Tommasi N, Braca A (2016) Drug affinity responsive target stability (DARTS) identifies Laurifolioside as a new Clathrin heavy chain modulator. J Nat Prod 79(10):2681\u20132692. https:\/\/doi.org\/10.1021\/acs.jnatprod.6b00627","journal-title":"J Nat Prod"},{"key":"813_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev.pharmtox.48.113006.094723","volume":"49","author":"S Shangary","year":"2009","unstructured":"Shangary S, Wang S (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49:223\u2013241. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.113006.094723","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"813_CR26","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.4161\/cc.10.10.15519","volume":"10","author":"IM van Leeuwen","year":"2011","unstructured":"van Leeuwen IM, Higgins M, Campbell J, Brown CJ, McCarthy AR, Pirrie L, Westwood NJ, La\u00edn S (2011) Mechanism-specific signatures for small-molecule p53 activators. Cell Cycle 10:1590\u20131598","journal-title":"Cell Cycle"},{"issue":"9","key":"813_CR27","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/onc.2011.309","volume":"31","author":"J de Lange","year":"2012","unstructured":"de Lange J, Ly LV, Lodder K, Verlaan-de Vries M, Teunisse AF, Jager MJ, Jochemsen AG (2012) Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma. Oncogene 31(9):1105\u20131116. https:\/\/doi.org\/10.1038\/onc.2011.309","journal-title":"Oncogene"},{"key":"813_CR28","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/978-1-493-2269-7_22","volume":"1263","author":"MY Pai","year":"2015","unstructured":"Pai MY, Lomenick B, Hwang H, Schiestel R, McBride W, Loo JA, Huang J (2015) Drug affinity responsive target stability (DARTS) for small-molecule target identification. Methods Mol Biol 1263:287\u2013298. https:\/\/doi.org\/10.1007\/978-1-493-2269-7_22","journal-title":"Methods Mol Biol"},{"issue":"7","key":"813_CR29","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.bcp.2007.07.003","volume":"74","author":"CR Arthur","year":"2007","unstructured":"Arthur CR, Gupton JT, Kellogg GE, Yeudall WA, Cabot MC, Newsham IF, Gewirtz DA (2007) Autophagic cell death, polyploidy and senescence induced in breast tumor cells by the substituted pyrrole JG-03-14, a novel microtubule poison. Biochem Pharmacol 74(7):981\u2013991","journal-title":"Biochem Pharmacol"},{"key":"813_CR30","doi-asserted-by":"publisher","unstructured":"Yoshii SR and Mizushima N ( 2017) Monitoring and measuring autophagy. Int J Mol Sci 18(9). Pii: E1865. https:\/\/doi.org\/10.3390\/ijms18091865","DOI":"10.3390\/ijms18091865"},{"key":"813_CR31","doi-asserted-by":"publisher","unstructured":"Manzano JL, Layos L, Bug\u00e9s C, de Los Llanos Gil M, Vila L, Mart\u00ednez-Balibrea E, Mart\u00ednez-Card\u00fas A (2016) Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med 4(12):237. https:\/\/doi.org\/10.21037\/atm.2016.06.07","DOI":"10.21037\/atm.2016.06.07"},{"issue":"44","key":"813_CR32","doi-asserted-by":"publisher","first-page":"78174","DOI":"10.18632\/oncotarget.19836","volume":"8","author":"M Griffin","year":"2017","unstructured":"Griffin M, Scotto D, Josephs DH, Mele S, Crescioli S, Bax HJ, Pellizzari G, Wynne MD, Nakamura M, Hoffmann RM, Ilieva KM, Cheung A, Spicer JF, Papa S, Lacy KE, Karagiannis SN (2017) BRAF inhibitors: resistance and the promise of combination treatments for melanoma. Oncotarget 8(44):78174\u201378192. https:\/\/doi.org\/10.18632\/oncotarget.19836","journal-title":"Oncotarget"},{"key":"813_CR33","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/humu.20481","volume":"28","author":"T Hocker","year":"2007","unstructured":"Hocker T, Tsao H (2007) Ultraviolet radiation and melanoma: a systemic review and analysis of reported sequence variants. Hum Mutat 28:588","journal-title":"Hum Mutat"},{"issue":"12","key":"813_CR34","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nrc2763","volume":"9","author":"CJ Brown","year":"2009","unstructured":"Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (2009) Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9(12):862\u2013873. https:\/\/doi.org\/10.1038\/nrc2763","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"813_CR35","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/j.febslet.2014.05.008","volume":"588","author":"M Lu","year":"2014","unstructured":"Lu M, Miller P, Lu X (2014) Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy. FEBS Lett 588(16):2616\u20132621. https:\/\/doi.org\/10.1016\/j.febslet.2014.05.008","journal-title":"FEBS Lett"},{"issue":"47","key":"813_CR36","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.1038\/onc.2017.258","volume":"36","author":"AN Hata","year":"2017","unstructured":"Hata AN, Rowley S, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Ji F, Jung J, Light M, Lee JS, Debussche L, Sidhu S, Sadreyev RI, Watters J, Engelman JA (2017) Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers. Oncogene 36(47):6581\u20136591. https:\/\/doi.org\/10.1038\/onc.2017.258","journal-title":"Oncogene"},{"issue":"1","key":"813_CR37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1158\/0008-5472.CAN-06-1538","volume":"67","author":"KS Smalley","year":"2007","unstructured":"Smalley KS, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS, Bregman H, Flaherty KT, Soengas MS, Meggers E, Herlyn M (2007) An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res 67(1):209\u2013217. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1538","journal-title":"Cancer Res"},{"issue":"6","key":"813_CR38","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1073\/pnas.0507493103","volume":"103","author":"C Tovar","year":"2006","unstructured":"Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT (2006) Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A 103(6):1888\u20131893. https:\/\/doi.org\/10.1073\/pnas.0507493103","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"813_CR39","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1158\/1078-0432.CCR-13-0074","volume":"19","author":"Z Ji","year":"2013","unstructured":"Ji Z, Kumar R, Taylor M, Rajadurai A, Marzuka-Alcal\u00e1 A, Chen YE, Njauw CN, Flaherty K, J\u00f6nsson G, Tsao H (2013) Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth. Clin Cancer Res 19(16):4383\u20134391. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0074","journal-title":"Clin Cancer Res"},{"issue":"32","key":"813_CR40","doi-asserted-by":"publisher","first-page":"52166","DOI":"10.18632\/oncotarget.10700","volume":"7","author":"SK Sutton","year":"2016","unstructured":"Sutton SK, Carter DR, Kim P, Tan O, Arndt GM, Zhang XD, Baell J, Noll BD, Wang S, Kumar N, McArthur GA, Cheung BB, Marshall GM (2016) A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner. Oncotarget 7(32):52166\u201352178. https:\/\/doi.org\/10.18632\/oncotarget.10700","journal-title":"Oncotarget"},{"issue":"4","key":"813_CR41","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1038\/oncsis.2017.11","volume":"6","author":"G Aga\u00ebsse","year":"2017","unstructured":"Aga\u00ebsse G, Barbollat-Boutrand L, El Kharbili M, Berthier-Vergnes O, Masse I (2017) p53 targets TSPAN8 to prevent invasion in melanoma cells. Oncogenesis. 6(4):e309. https:\/\/doi.org\/10.1038\/oncsis.2017.11","journal-title":"Oncogenesis."},{"issue":"2","key":"813_CR42","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cell.2013.08.062","volume":"155","author":"SL Spencer","year":"2013","unstructured":"Spencer SL, Cappell SD, Tsai FC, Overton KW, Wang CL, Meyer T (2013) The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit. Cell 155(2):369\u2013383. https:\/\/doi.org\/10.1016\/j.cell.2013.08.062","journal-title":"Cell"},{"issue":"10","key":"813_CR43","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc1716","volume":"5","author":"L Whitesell","year":"2005","unstructured":"Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5(10):761\u2013772. https:\/\/doi.org\/10.1038\/nrc1716","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"813_CR44","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrm.2017.20","volume":"18","author":"FH Schopf","year":"2017","unstructured":"Schopf FH, Biebl MM, Buchner J (2017) The HSP90 chaperone machinery. Nat Rev Mol Cell Biol 18(6):345\u2013360. https:\/\/doi.org\/10.1038\/nrm.2017.20","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"16","key":"813_CR45","doi-asserted-by":"publisher","first-page":"8379","DOI":"10.1073\/pnas.93.16.8379","volume":"93","author":"MV Blagosklonny","year":"1996","unstructured":"Blagosklonny MV, Toretsky J, Bohen S, Neckers L (1996) Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci U S A 93(16):8379\u20138383","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"813_CR46","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nsmb.2114","volume":"18","author":"F Hagn","year":"2011","unstructured":"Hagn F, Lagleder S, Retzlaff M, Rohrberg J, Demmer O, Richter K, Buchner J, Kessler H (2011) Structural analysis of the interaction between Hsp90 and the tumor suppressor protein p53. Nat Struct Mol Biol 18(10):1086\u20131093. https:\/\/doi.org\/10.1038\/nsmb.2114","journal-title":"Nat Struct Mol Biol"},{"issue":"47","key":"813_CR47","doi-asserted-by":"publisher","first-page":"48846","DOI":"10.1074\/jbc.M407687200","volume":"279","author":"L M\u00fcller","year":"2004","unstructured":"M\u00fcller L, Schaupp A, Walerych D, Wegele H, Buchner J (2004) Hsp90 regulates the activity of wild type p53 under physiological and elevated temperatures. J Biol Chem 279(47):48846\u201348854. https:\/\/doi.org\/10.1074\/jbc.M407687200","journal-title":"J Biol Chem"},{"issue":"47","key":"813_CR48","doi-asserted-by":"publisher","first-page":"48836","DOI":"10.1074\/jbc.M407601200","volume":"279","author":"D Walerych","year":"2004","unstructured":"Walerych D, Kudla G, Gutkowska M, Wawrzynow B, Muller L, King FW, Helwak A, Boros J, Zylicz A, Zylicz M (2004) Hsp90 chaperones wild-type p53 tumor suppressor protein. J Biol Chem 279(47):48836\u201348845. https:\/\/doi.org\/10.1074\/jbc.M407601200","journal-title":"J Biol Chem"},{"issue":"2","key":"813_CR49","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/1535-7163.MCT-13-0481","volume":"13","author":"J Acquaviva","year":"2014","unstructured":"Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA (2014) Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Mol Cancer Ther 13(2):353\u2013363. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0481","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"813_CR50","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41467-017-00449-z","volume":"8","author":"RM Mbofung","year":"2017","unstructured":"Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C et al (2017) HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nat Commun 8(1):451. https:\/\/doi.org\/10.1038\/s41467-017-00449-z","journal-title":"Nat Commun"},{"issue":"12","key":"813_CR51","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1158\/1535-7163.MCT-10-0646","volume":"9","author":"HY Tseng","year":"2010","unstructured":"Tseng HY, Jiang CC, Croft A, Tay KH, Thorne RF, Yang F, Liu H, Hersey P, Zhang XD (2010) Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells. Mol Cancer Ther 9(12):3363\u20133374. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0646","journal-title":"Mol Cancer Ther"},{"key":"813_CR52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-2407-10-57","volume":"10","author":"SV Tokalov","year":"2010","unstructured":"Tokalov SV, Abolmaali ND (2010) Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment. BMC Cancer 10:57","journal-title":"BMC Cancer"},{"key":"813_CR53","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1158\/1541-7786.MCR-09-0144","volume":"7","author":"B Huang","year":"2009","unstructured":"Huang B, Deo D, Xia M, Vassilev LT (2009) Pharmacologic p53 activation blocks cell cycle progression but fails to induce senescence in epithelial cancer cells. Mol Cancer Res 7:1497\u20131509","journal-title":"Mol Cancer Res"},{"issue":"4","key":"813_CR54","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1158\/1541-7786.MCR-08-0358","volume":"7","author":"K Boisvert-Adamo","year":"2009","unstructured":"Boisvert-Adamo K, Longmate W, Abel EV, Aplin AE (2009) Mcl-1 is required for melanoma cell resistance to anoikis. Mol Cancer Res 7(4):549\u2013556. https:\/\/doi.org\/10.1158\/1541-7786.MCR-08-0358","journal-title":"Mol Cancer Res"},{"issue":"10","key":"813_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139254","volume":"10","author":"G Borthakur","year":"2015","unstructured":"Borthakur G, Duvvuri S, Ruvolo V, Tripathi DN, Piya S, Burks J, Jacamo R, Kojima K, Ruvolo P, Fueyo-Margareto J, Konopleva M, Andreeff M (2015) MDM2 inhibitor, Nutlin 3a, induces p53 dependent autophagy in acute leukemia by AMP kinase activation. PLoS One 10(10):e0139254. https:\/\/doi.org\/10.1371\/journal.pone.0139254","journal-title":"PLoS One"},{"issue":"11","key":"813_CR56","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/15384047.2017.1345397","volume":"18","author":"B Davaadelger","year":"2017","unstructured":"Davaadelger B, Perez RE, Zhou Y, Duan L, Gitelis S, Maki CG (2017) The IGF-1R\/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis. Cancer Biol Ther 18(11):895\u2013903. https:\/\/doi.org\/10.1080\/15384047.2017.1345397","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"813_CR57","doi-asserted-by":"publisher","first-page":"10498","DOI":"10.18632\/oncotarget.14443","volume":"8","author":"KM Vincent","year":"2017","unstructured":"Vincent KM, Postovit LM (2017) Investigating the utility of human melanoma cell lines as tumour models. Oncotarget 8(6):10498\u201310509. https:\/\/doi.org\/10.18632\/oncotarget.14443","journal-title":"Oncotarget"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00813-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00813-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00813-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:35:06Z","timestamp":1678509306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00813-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,26]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["813"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00813-4","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,26]]},"assertion":[{"value":"2 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Maria Chiara Proto declares that she has no conflict of interest. Donatella Fiore declares that she has no conflict of interest. Giovanni Forte declares that he has no conflict of interest. Paola Cuozzo declares that she has no conflict of interest. Anna Ramunno declares that she has no conflict of interest. Caterina Fattorusso declares that she has no conflict of interest. Patrizia Gazzerro declares that she has no conflict of interest. Maria Pascale declares that she has no conflict of interest. Silvia Franceschelli declares that she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}